Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian Cancer

• Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced that data from the Phase 2 trial of relacorilant plus nab-paclitaxel were presented at the European Society for Medical Oncology (ESMO21) Congress 2021.

• The trial included 178 patients with recurrent platinum-resistant ovarian cancer.

• Women who received the higher dose of relacorilant (150 mg) intermittently exhibited a statistically significant improvement in median progression-free survival (PFS) compared to those who received nab-paclitaxel alone (median PFS: 5.6 months versus 3.8 months).

• The women in the Intermittent arm also experienced a statistically significant improvement in the duration of response (DoR) relative to those in the Comparator arm (median DoR: 5.6 months versus 3.7 months).

• But the Company reported the median overall survival (OS) of 12.9 months versus 10.4 months in the Comparator arm.

• Corcept will begin a pivotal Phase 3 trial in Q1 of 2022.

• Price Action: CORT shares are down 1.94% at $20.23 during the market session on the last check Friday.

• Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

See more from Benzinga

• Click here for options trades from Benzinga

• What Is Happening With Innate Pharma Stock On Friday?

• FDA Reveals COVID-19 Booster Advisory Committee Question

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.